Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Orforglipron

Orforglipron

GLP-1 (small molecule) · oral · Eli Lilly

Data cut 12 November 2026 · page built 16 November 2026 · 12 trial arms · 9 trials with results · 27 registered trials · see on the pipeline board

Summary

Also known as
LY3502970
Mechanism
GLP-1 (small molecule)
Route
oral
Company
Eli Lilly
Highest development stage
approved
Status (as of data cut)
Approved in the US for obesity (Foundayo, 2026); T2D phase 3 positive (ACHIEVE) verify
Next milestone
T2D filing; CV outcomes trial ongoing

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity4 approved / in labelFDA: Foundayo (2026)Foundayo US label (2026); ATTAIN-1
T2D3 positive phase 3Positive phase 3 programme (ACHIEVE); not yet labelled for T2DACHIEVE-1; ACHIEVE-4 (EASD 2026)
CV outcomes3 positive phase 3ACHIEVE-4 met MACE non-inferiority versus insulin glargine; a placebo-controlled CV outcomes trial is ongoingACHIEVE-4 (EASD 2026); CVOT (ongoing)
CKD1 phase 2 / signalSlower eGFR decline versus glargine as a secondary outcome in ACHIEVE-4ACHIEVE-4 kidney outcomes (EASD 2026)
HFpEF0 no data
MASH0 no data
Sleep apnoea3 positive phase 3Positive phase 3: ATTAIN-OSA (JAMA, Nov 2026)ATTAIN-OSA, JAMA 2026; ATTAIN-OSA
Knee OA2 phase 3 ongoingPhase 3 ongoing
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

US prescribing information: indications

Verbatim section 1 of the current FDA label (DailyMed), as checked by the atlas.

FOUNDAYO US label 29.07.2026

1 INDICATIONS AND USAGE FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended.

DailyMed

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
ACHIEVE-1orforglipron 36 mgt2d40559−7.9 % vs −1.6 %
Δ −6.3 pp
−7.6 % vs −1.7 %
Δ −5.9 pp
−1.5 vs −0.47.8 vs 1.49.9 vs 7.216.3 vs 2.214.2 vs 1.42.8 vs 3.6—verified
ACHIEVE-2 (vs dapagliflozin)orforglipron 3 mg vs dapagliflozin 10 mg (active)t2d40240——−3.5 %
estimand not specified
−1.3——19.67.93.3—verified
ACHIEVE-2 (vs dapagliflozin)orforglipron 12 mg vs dapagliflozin 10 mg (active)t2d40241——−6.3 %
estimand not specified
−1.7——17.88.35.8—verified
ACHIEVE-2 (vs dapagliflozin)orforglipron 36 mg vs dapagliflozin 10 mg (active)t2d40241——−7.3 %
estimand not specified
−1.7——22.412.04.1—verified
ACHIEVE-4 (vs insulin glargine)orforglipron 36 mg or MTD vs insulin glargine (active)t2d52—−8.8 %−7.8 %−1.515.430.9 vs 20.531.921.016.2—verified
ATTAIN-1orforglipron 36 mgobesity723127−12.4 % vs −0.9 %
Δ −11.5 pp
−11.2 % vs −2.1 %
Δ −9.1 pp
—10.3 vs 2.724.4 vs 29.9——3.8 vs 4.9—verified
ATTAIN-2 (obesity + T2D)orforglipron 6 mgt2d721613−5.5 % vs −2.2 %
Δ −3.3 pp
−5.1 % vs −2.5 %
Δ −2.6 pp
−1.2 vs −0.56.1 vs 4.619.1 vs 20.020.1 vs 8.412.8 vs 3.87.3 vs 8.8—verified
ATTAIN-2 (obesity + T2D)orforglipron 12 mgt2d721613−7.8 % vs −2.2 %
Δ −5.6 pp
−7.0 % vs −2.5 %
Δ −4.5 pp
−1.5 vs −0.510.6 vs 4.622.3 vs 20.031.1 vs 8.420.2 vs 3.810.3 vs 8.8—verified
ATTAIN-2 (obesity + T2D)orforglipron 36 mgt2d721613−10.5 % vs −2.2 %
Δ −8.3 pp
−9.6 % vs −2.5 %
Δ −7.1 pp
−1.7 vs −0.510.6 vs 4.620.5 vs 20.036.4 vs 8.423.1 vs 3.810.9 vs 8.8—verified
ATTAIN-J (Japan)orforglipron 6 mgobesity7261—−5.9 % vs −0.6 %
Δ −5.3 pp
———————verified
ATTAIN-J (Japan)orforglipron 12 mgobesity7257—−8.7 % vs −0.6 %
Δ −8.1 pp
———————verified
ATTAIN-J (Japan)orforglipron 36 mgobesity7260—−7.9 % vs −0.6 %
Δ −7.3 pp
———————verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (62)
  • orforglipron 36 mg · weight_eff · Figure 1B (garbled text; arm mapping inferred from ETDs)
    −7.8 −12.4 −0.9 −9.3 ETD, −11.5 percentage points (95% CI, −12.3 to −10.6) ETD, −8.4 percentage points (95% CI, −9.2 to −7.6) ETD, −6.9 percentage points
  • orforglipron 36 mg · weight_tp · Table 2
    −7.5 (−8.2 to −6.8) −8.4 (−9.1 to −7.7) −11.2 (−12.0 to −10.4) −2.1 (−2.8 to −1.4)
  • orforglipron 36 mg · ae_dc · Table 4
    Any adverse event 38 (5.3) 57 (7.9) 75 (10.3) 26 (2.7) 196 (6.3)
  • orforglipron 36 mg · disc_any · Results, Patients; computed from 552 (75.6%) of 730 continui
    the percentage of patients who discontinued treatment for any reason was 25.0% (21.9 to 24.4% in the orforglipron groups and 29.9% in the placebo group)
  • orforglipron 36 mg · sae · Table 4
    Serious adverse event 40 (5.5) 39 (5.4) 28 (3.8) 46 (4.9) 153 (4.9)
  • orforglipron 6 mg · weight_tp · Summary / Table 2 (treatment regimen estimand)
    the mean percent change in bodyweight from baseline to week 72 was –5·1% (95% CI –6·0 to –4·2) with 6 mg (estimated treatment difference [ETD] –2·7 [95% CI –3·7 to –1·6]; p<0·0001)
  • orforglipron 6 mg · weight_eff · Results, efficacy estimand (figure 2B)
    For the efficacy estimand, the mean percent change from baseline in bodyweight to week 72 was -5.5% (95% CI -6.2 to -4.8) or -5.5 kg with orforglipron 6 mg, -7.8% (-8.6 to -7.0) or -7.9 kg with orforglipron 12 mg, -10.5% (-11.5 to -9.6) or -10.4 kg with orforglipron 36 mg, and -2.2% (-2.6 to -1.8) or -2.3 kg with placebo
  • orforglipron 6 mg · ae_dc · Table 4
    Adverse events leading to discontinuation of study drug 20 (6·1%) 35 (10·6%) 34 (10·6%) 29 (4·6%)
  • orforglipron 6 mg · disc_any · Figure 1 trial profile; computed: 63/329 vs 126/630 with placebo
    63 discontinued intervention
  • orforglipron 6 mg · nausea · Table 4
    Nausea 66 (20·1%) 103 (31·1%) 117 (36·4%) 53 (8·4%)
  • orforglipron 6 mg · vomiting · Table 4
    Vomiting 42 (12·8%) 67 (20·2%) 74 (23·1%) 24 (3·8%)
  • orforglipron 6 mg · sae · Table 4
    Serious adverse events 24 (7·3%) 34 (10·3%) 35 (10·9%) 55 (8·8%)
  • orforglipron 6 mg · hba1c · Table 2
    Change in HbA1c, % (95% CI) –1·22 (–1·36 to –1·08) –1·50 (–1·62 to –1·38) –1·66 (–1·77 to –1·55) –0·47 (–0·58 to –0·36) Treatment comparison (95% CI); p value ETD –0·76 (–0·93 to –0·58); p<0·0001 ETD –1·03 (–1·19 to –0·87); p<0·0001 ETD –1·20 (–1·35 to –1·04); p<0·0001
  • orforglipron 12 mg · weight_tp · Summary / Table 2 (treatment regimen estimand)
    –7·0% (–7·8 to –6·2) with 12 mg (ETD –4·5 [–5·5 to –3·6]; p<0·0001)
  • orforglipron 12 mg · weight_eff · Results, efficacy estimand (figure 2B)
    For the efficacy estimand, the mean percent change from baseline in bodyweight to week 72 was -5.5% (95% CI -6.2 to -4.8) or -5.5 kg with orforglipron 6 mg, -7.8% (-8.6 to -7.0) or -7.9 kg with orforglipron 12 mg, -10.5% (-11.5 to -9.6) or -10.4 kg with orforglipron 36 mg, and -2.2% (-2.6 to -1.8) or -2.3 kg with placebo
  • orforglipron 12 mg · ae_dc · Table 4
    Adverse events leading to discontinuation of study drug 20 (6·1%) 35 (10·6%) 34 (10·6%) 29 (4·6%)
  • orforglipron 12 mg · disc_any · Figure 1 trial profile; computed: 74/332 vs 126/630 with placebo
    74 discontinued intervention
  • orforglipron 12 mg · nausea · Table 4
    Nausea 66 (20·1%) 103 (31·1%) 117 (36·4%) 53 (8·4%)
  • orforglipron 12 mg · vomiting · Table 4
    Vomiting 42 (12·8%) 67 (20·2%) 74 (23·1%) 24 (3·8%)
  • orforglipron 12 mg · sae · Table 4
    Serious adverse events 24 (7·3%) 34 (10·3%) 35 (10·9%) 55 (8·8%)
  • orforglipron 12 mg · hba1c · Table 2
    Change in HbA1c, % (95% CI) –1·22 (–1·36 to –1·08) –1·50 (–1·62 to –1·38) –1·66 (–1·77 to –1·55) –0·47 (–0·58 to –0·36) Treatment comparison (95% CI); p value ETD –0·76 (–0·93 to –0·58); p<0·0001 ETD –1·03 (–1·19 to –0·87); p<0·0001 ETD –1·20 (–1·35 to –1·04); p<0·0001
  • orforglipron 36 mg · weight_tp · Summary / Table 2 (treatment regimen estimand)
    –9·6% (–10·5 to –8·7) with 36 mg orforglipron (ETD –7·1 [–8·2 to –6·1]; p<0·0001)
  • orforglipron 36 mg · weight_eff · Results, efficacy estimand (figure 2B)
    For the efficacy estimand, the mean percent change from baseline in bodyweight to week 72 was -5.5% (95% CI -6.2 to -4.8) or -5.5 kg with orforglipron 6 mg, -7.8% (-8.6 to -7.0) or -7.9 kg with orforglipron 12 mg, -10.5% (-11.5 to -9.6) or -10.4 kg with orforglipron 36 mg, and -2.2% (-2.6 to -1.8) or -2.3 kg with placebo
  • orforglipron 36 mg · ae_dc · Table 4
    Adverse events leading to discontinuation of study drug 20 (6·1%) 35 (10·6%) 34 (10·6%) 29 (4·6%)
  • orforglipron 36 mg · disc_any · Figure 1 trial profile; computed: 66/322 vs 126/630 with placebo
    66 discontinued intervention
  • orforglipron 36 mg · nausea · Table 4
    Nausea 66 (20·1%) 103 (31·1%) 117 (36·4%) 53 (8·4%)
  • orforglipron 36 mg · vomiting · Table 4
    Vomiting 42 (12·8%) 67 (20·2%) 74 (23·1%) 24 (3·8%)
  • orforglipron 36 mg · sae · Table 4
    Serious adverse events 24 (7·3%) 34 (10·3%) 35 (10·9%) 55 (8·8%)
  • orforglipron 36 mg · hba1c · Table 2
    Change in HbA1c, % (95% CI) –1·22 (–1·36 to –1·08) –1·50 (–1·62 to –1·38) –1·66 (–1·77 to –1·55) –0·47 (–0·58 to –0·36) Treatment comparison (95% CI); p value ETD –0·76 (–0·93 to –0·58); p<0·0001 ETD –1·03 (–1·19 to –0·87); p<0·0001 ETD –1·20 (–1·35 to –1·04); p<0·0001
  • orforglipron 36 mg · weight_eff · Figure 2B (end-of-curve labels, efficacy estimand; garbled o
    −4.7% (−4.4 kg) −7.9% (−7.3 kg) −1.6% (−1.3 kg) −6.1% (−5.5 kg)
  • orforglipron 36 mg · weight_tp · Results, End Points paragraph; Figure 2A
    −7.6% (95% CI, −8.8 to −6.4) with the 36-mg dose
  • orforglipron 36 mg · ae_dc · Table 2
    Adverse event leading to discontinuation of orforglipron or placebo 8 (5.6) 6 (4.4) 11 (7.8) 2 (1.4) 27 (4.8)
  • orforglipron 36 mg · nausea · Table 2
    Nausea 18 (12.6) 25 (18.2) 23 (16.3) 3 (2.2) 69 (12.3)
  • orforglipron 36 mg · vomiting · Table 2
    Vomiting 7 (4.9) 9 (6.6) 20 (14.2) 2 (1.4) 38 (6.8)
  • orforglipron 36 mg · sae · Table 2
    Any serious adverse event 8 (5.6) 7 (5.1) 4 (2.8) 5 (3.6) 24 (4.3)
  • orforglipron 36 mg · hba1c · Abstract; Results, End Points
    −1.48 percentage points with the 36-mg dose
  • orforglipron 36 mg · disc_any · Results, Participants
    and 504 par- ticipants (90.2%; 129 in the 3-mg group, 120 in the 12-mg group, 127 in the 36-mg group, and 128 in the placebo group) continued to receive orforglipron or placebo throughout the 40-week
  • orforglipron 36 mg or MTD · weight_eff · Table (week 52)
    52 | -8.76% | 1.66%
  • orforglipron 36 mg or MTD · hba1c · Table (week 52)
    Orforglipron | -1.46
  • orforglipron 36 mg or MTD · disc_any · Results, disposition
    2044 (74·4%) of 2749 completed the study on treatment (948 [69·1%] of 1371 assigned to orforglipron and 1096 [79·5%] of 1378 assigned to insulin glargine). The
  • orforglipron 36 mg or MTD · ae_dc · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
    Adverse events leading to study treatment discontinuation 211 (15·4%) 73 (5·4%)
  • orforglipron 36 mg or MTD · nausea · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
    Nausea 438 (31·9%) 19 (1·4%)
  • orforglipron 36 mg or MTD · vomiting · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
    Vomiting 288 (21·0%) 22 (1·6%)
  • orforglipron 36 mg or MTD · sae · Table 3 (orforglipron n=1371, insulin glargine n=1355; on-tr
    Serious adverse events 222 (16·2%) 255 (18·8%)
  • orforglipron 3 mg · weight_unsp · ClinicalTrials.gov results tables
    ClinicalTrials.gov results, Orforglipron 3 mg: HbA1c -1.32; body weight -3.5 %; withdrawals for adverse events 3/240
  • orforglipron 3 mg · hba1c · ClinicalTrials.gov results tables
    ClinicalTrials.gov results, Orforglipron 3 mg: HbA1c -1.32; body weight -3.5 %; withdrawals for adverse events 3/240
  • orforglipron 3 mg · nausea · CT.gov adverse events, Other events: Nausea
    "groupId": "EG000", "numEvents": 60, "numAffected": 47, "numAtRisk": 240
  • orforglipron 3 mg · vomiting · CT.gov adverse events, Other events: Vomiting
    "groupId": "EG000", "numEvents": 22, "numAffected": 19, "numAtRisk": 240
  • orforglipron 3 mg · sae · CT.gov event groups
    "id": "EG000", "title": "Orforglipron 3 mg", "description": "Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated at week 4 to a dose of 3 mg, which was then maintained up
  • orforglipron 12 mg · weight_unsp · ClinicalTrials.gov results tables
    ClinicalTrials.gov results, Orforglipron 12 mg: HbA1c -1.74; body weight -6.3 %; withdrawals for adverse events 3/241
  • orforglipron 12 mg · hba1c · ClinicalTrials.gov results tables
    ClinicalTrials.gov results, Orforglipron 12 mg: HbA1c -1.74; body weight -6.3 %; withdrawals for adverse events 3/241
  • orforglipron 12 mg · nausea · CT.gov adverse events, Other events: Nausea
    "groupId": "EG001", "numEvents": 57, "numAffected": 43, "numAtRisk": 241
  • orforglipron 12 mg · vomiting · CT.gov adverse events, Other events: Vomiting
    "groupId": "EG001", "numEvents": 34, "numAffected": 20, "numAtRisk": 241
  • orforglipron 12 mg · sae · CT.gov event groups
    "id": "EG001", "title": "Orforglipron 12 mg", "description": "Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks (to 3 mg at week 4 and 6 mg at week 8) unti
  • orforglipron 36 mg · weight_unsp · ClinicalTrials.gov results tables
    ClinicalTrials.gov results, Orforglipron 36 mg: HbA1c -1.73; body weight -7.3 %; withdrawals for adverse events 6/241
  • orforglipron 36 mg · hba1c · ClinicalTrials.gov results tables
    ClinicalTrials.gov results, Orforglipron 36 mg: HbA1c -1.73; body weight -7.3 %; withdrawals for adverse events 6/241
  • orforglipron 36 mg · nausea · CT.gov adverse events, Other events: Nausea
    "groupId": "EG002", "numEvents": 70, "numAffected": 54, "numAtRisk": 241
  • orforglipron 36 mg · vomiting · CT.gov adverse events, Other events: Vomiting
    "groupId": "EG002", "numEvents": 50, "numAffected": 29, "numAtRisk": 241
  • orforglipron 36 mg · sae · CT.gov event groups
    "id": "EG002", "title": "Orforglipron 36 mg", "description": "Participants received orforglipron, administered orally QD, starting at a dose of 1 mg and escalated every 4 weeks (to 3 mg at week 4, 6 mg at week 8, 12 mg a
  • orforglipron 6 mg · weight_tp · Abstract, Findings
    mean percentage change in bodyweight was -5·9% (95% CI -7·6 to -4·2) with orforglipron 6 mg
  • orforglipron 12 mg · weight_tp · Abstract, Findings
    -8·7% (-10·9 to -6·5) with 12 mg
  • orforglipron 36 mg · weight_tp · Abstract, Findings
    and -7·9% (-10·0 to -5·8) with 36 mg

Outcome trials

Cardiovascular and kidney outcome trials

ACHIEVE-4 orforglipron 36 mg or maximum tolerated dose (oral, once daily) vs insulin glargine (active) · T2D at increased CV risk (86 % established CVD, 38 % CKD) · n = 2749 · 2026 verified

EndpointHR95 % CIEvents, drug vs controlStatus
4-point MACE primary
MACE-4: composite of non-fatal myocardial infarction, non-fatal stroke, hospitalisation for unstable angina, or cardiovascular death (primary endpoint; non-inferiority, safety analysis set)
0.840.59–1.2057 vs 67verified
3-point MACE
MACE-3: composite of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death (key secondary endpoint; superiority, randomised participants excluding GCP-closed sites)
0.770.52–1.1346 vs 59verified
Cardiovascular death
Cardiovascular death (component of MACE-4; deaths of undetermined cause counted as CV deaths)
0.470.25–0.9014 vs 29verified
Myocardial infarction
Non-fatal myocardial infarction (component of MACE-4) — non-fatal events only
0.850.46–1.5819 vs 22verified
Stroke
Non-fatal stroke (component of MACE-4) — non-fatal events only
0.980.47–2.0614 vs 14verified
Hospitalisation for unstable angina
Hospitalisation for unstable angina (component of MACE-4)
1.550.67–3.5814 vs 9verified
Verbatim quotes (6)
  • 4-point MACE · Table 2
    p value MACE-4 (primary endpoint)* 57/1358 (4·2%) 67/1343 (5·0%) 0·84 (0·59-1·20)
  • 3-point MACE · Table 2
    47-2·06) ·· Hospitalisation for unstable angina 14/1358 (1·0%) 9/1343 (0·7%) 1·55 (0·67-3·58) ·· MACE-3 (key secondary endpoint)* 46/1358 (3·4%) 59/1366 (4·3%) 0·77 (0·52-1·13)
  • Cardiovascular death · Table 2
    p value MACE-4 (primary endpoint)* 57/1358 (4·2%) 67/1343 (5·0%) 0·84 (0·59-1·20) <0·0001 (non- inferiority) Cardiovascular death 14/1358 (1·0%) 29/1343 (2·2%) 0·47 (0·25-0·90)
  • Myocardial infarction · Table 2
    <0·0001 (non- inferiority) Cardiovascular death 14/1358 (1·0%) 29/1343 (2·2%) 0·47 (0·25-0·90) ·· Non-fatal myocardial infarction 19/1358 (1·4%) 22/1343 (1·6%) 0·85 (0·46-1·58)
  • Stroke · Table 2
    343 (2·2%) 0·47 (0·25-0·90) ·· Non-fatal myocardial infarction 19/1358 (1·4%) 22/1343 (1·6%) 0·85 (0·46-1·58) ·· Non-fatal stroke 14/1358 (1·0%) 14/1343 (1·0%) 0·98 (0·47-2·06)
  • Hospitalisation for unstable angina · Table 2
    (1·6%) 0·85 (0·46-1·58) ·· Non-fatal stroke 14/1358 (1·0%) 14/1343 (1·0%) 0·98 (0·47-2·06) ·· Hospitalisation for unstable angina 14/1358 (1·0%) 9/1343 (0·7%) 1·55 (0·67-3·58)

Other indications

ATTAIN-OSA trial 1 / trial 2 Orforglipron · Obstructive sleep apnoea + obesity or overweight (no T2D) · 52 weeks · n = 712 abstract

AHI −13.2 (trial 1, no PAP) and −12.0 (trial 2, on PAP) events/h vs placebo at 52 weeks, treatment-regimen estimand; 6 of 7 key secondary end points significant.

MeasureDrugControlDifference (95 % CI)Status
Apnea-hypopnea index, change from baseline (treatment-regimen estimand) ATTAIN-OSA Trial 1, no PAP
week 52
−17.8−4.5−13.2 (−17.7 to −8.7) events/habstract
Apnea-hypopnea index, change from baseline (treatment-regimen estimand) ATTAIN-OSA Trial 2, on PAP
week 52
−17.3−5.3−12.0 (−17.1 to −6.9) events/habstract
Verbatim quotes (2)
  • Apnea-hypopnea index, change from baseline (treatment-regimen estimand)
    in trial 1, the mean AHI change was -17.8 for orforglipron compared with -4.5 for placebo (difference, -13.2 [95% CI, -17.7 to -8.7]; P < .001)
  • Apnea-hypopnea index, change from baseline (treatment-regimen estimand)
    In trial 2, the mean AHI change was -17.3 for orforglipron and -5.3 for placebo (difference, -12.0 [95% CI, -17.1 to -6.9]; P < .001)

Ongoing outcome trials

TrialMoleculePopulationPrimary endpointnRegistry statusPrimary completionRegistry
Orforglipron CVOTOrforglipronAtherosclerotic CVD, obesity or T2D
ASCVD and/or CKD with obesity or T2D
MACE7140recruiting2031-08NCT07241390

Registered trials (27)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
ATTAIN-CN
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
ObesityPhase 3not yet recruiting2026-12 → 2028-03192not yet recruitingNCT07790861
ATTAIN-NOW
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
ObesityPhase 3recruiting2026-08 → 2029-082001recruitingNCT07794579
ACHIEVE-RAM
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting
T2DPhase 3recruiting2026-07 → 2027-05130recruitingNCT07613307
ACHIEVE-PEDS
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
T2DPhase 3recruiting2026-07 → 2030-03170recruitingNCT07668336
Orforglipron CVOT
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
CV outcomesPhase 3recruiting2025-12 → 2031-087140NCT07241390
ATTAIN-PAD
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
CV outcomesPhase 3recruiting2025-10 → 2028-061205recruitingNCT07223593
ATTAIN-OA PAIN
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Knee OAPhase 3active not recruiting2025-09 → 2028-04800active not recruitingNCT07153471
RESTRAIN-SUI
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
ObesityPhase 3recruiting2025-09 → 2028-031000recruitingNCT07202884
NCT06972459
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
ObesityPhase 3active not recruiting2025-05 → 2027-08800active not recruitingNCT06972459
NCT06972472
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
ObesityPhase 3active not recruiting2025-05 → 2027-08600active not recruitingNCT06972472
NCT06993792
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
ObesityPhase 3active not recruiting2025-05 → 2027-081400active not recruitingNCT06993792
ATTAIN-HYPERTENSION
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
HypertensionPhase 3active not recruiting2025-04 → 2027-09974active not recruitingNCT06948422
ATTAIN-HYPERTENSION
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
HypertensionPhase 3active not recruiting2025-04 → 2027-09487active not recruitingNCT06948435
ATTAIN-HYPERTENSION
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
HypertensionPhase 3active not recruiting2025-04 → 2027-09487active not recruitingNCT06952530
ADVANCE
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
ObesityPhase 3recruiting2024-11 → 2027-02125recruitingNCT06672549
NCT06672939
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
ObesityPhase 3recruiting2024-11 → 2027-12150recruitingNCT06672939
ATTAIN-OSA trial 1 / trial 2
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
CV outcomesPhase 3completed2024-10 → 2026-07712Completed; results not yet publicNCT06649045
ATTAIN-MAINTAIN
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
ObesityPhase 3completed2024-09 → 2025-11376Completed; results not in the atlas yetNCT06584916
ACHIEVE-2
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
T2DPhase 3completed2024-01 → 2025-09962Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT06192108
ACHIEVE-5
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
T2DPhase 3completed2023-11 → 2025-09546Completed; results not in the atlas yetNCT06109311
ACHIEVE-J
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
T2DPhase 3completed2023-09 → 2025-06401Completed; results not in the atlas yetNCT06010004
ACHIEVE-3
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
T2DPhase 3completed2023-09 → 2025-081698Completed; results not in the atlas yetNCT06045221
ACHIEVE-1
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
T2DPhase 3completed2023-08 → 2025-04559Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT05971940
ATTAIN-J
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
ObesityPhase 3completed2023-07 → 2025-06238Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT05931380
ATTAIN-1
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
ObesityPhase 3active not recruiting2023-06 → 2025-073127active not recruitingNCT05869903
ATTAIN-2
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
ObesityPhase 3completed2023-06 → 2025-081613Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT05872620
ACHIEVE-4
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
CV outcomesPhase 3completed2023-04 → 2026-0327494-point MACE HR 0.84 (0.59–1.20) vs insulin glargine: non-inferiorNCT05803421

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Orforglipron. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/orforglipron/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.